Drugs / GSK4172239D
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05660265 | Aug 2023 → Sep 2025 | sickle cell disease | GlaxoSmithKline | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK4172239D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05660265 ↗ |
| Route | Oral | “Oral GSK4172239D” NCT05660265 ↗ |